Yaky Yanay
2023
In 2023, Yaky Yanay earned a total compensation of $2.7M as CEO at Pluristem Therapeutics, a 111% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $128,058 |
|---|---|
| Salary | $414,086 |
| Stock Awards | $2,169,642 |
| Other | $33,787 |
| Total | $2,742,573 |
Yanay received $2.2M in stock awards, accounting for 79% of the total pay in 2023.
Yanay also received $128.1K in non-equity incentive plan, $414.1K in salary and $33.8K in other compensation.
Rankings
In 2023, Yaky Yanay's compensation ranked 344th out of 3,006 executives tracked by ExecPay. In other words, Yanay earned more than 88.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 344 out of 3,006 | 89th |
Division Manufacturing | 194 out of 1,650 | 88th |
Major group Chemicals And Allied Products | 133 out of 918 | 86th |
Industry group Drugs | 130 out of 881 | 85th |
Industry Biological Products, Except Diagnostic Substances | 45 out of 213 | 79th |
Source: SEC filing on May 1, 2024.
Yanay's colleagues
We found one more compensation record of an executive who worked with Yaky Yanay at Pluristem Therapeutics in 2023.
2023
Chen Franco-Yehuda
Pluristem Therapeutics
Chief Financial Officer
News
Pluristem Therapeutics CEO Yaky Yanay's 2023 pay jumps 111% to $2.7M
May 1, 2024
Pluristem Therapeutics CEO Yaky Yanay's 2022 pay falls 86% to $1.3M
February 27, 2023
Pluristem Therapeutics Chairman Zami Aberman's 2020 pay falls 54% to $501K
April 8, 2021
Pluristem Therapeutics Chairman Zami Aberman's 2019 pay jumps 85% to $1.1M
May 20, 2020
Pluristem Therapeutics CEO Zami Aberman's 2018 pay falls 83% to $593K
April 25, 2019